Timothy Eugene Sullivan, Chief Financial Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 137,958 shares at $88.36 ($12.2M) on 2023-06-05, disclosed to the SEC on 2023-06-06.
Scheduled sale ($12.2M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $87.79 | 30,609 | $2.7M | 21.9% |
| 2 | $87.79 | 30,609 | $2.7M | 21.9% |
| 3 | $88.36 | 7,064 | $624K | 5.1% |
| 4 | $88.36 | 7,064 | $624K | 5.1% |
| 5 | $89.83 | 30,506 | $2.7M | 22.4% |
| 6 | $89.83 | 30,506 |
| $2.7M |
| 22.4% |
| 7 | $90.60 | 1,600 | $145K | 1.2% |
| Total | $88.78 avg | 137,958 | $12.2M | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $86K | — | Filing → |
| APLS | SELL | 2025-10-23 | $280K | — | Filing → |
| APLS | SELL | 2025-09-10 | $2.1M | — | Filing → |